Trial Profile

A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (greater than or equal to 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

03 Dec 2020 Status changed from active, no longer recruiting to completed.
29 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
29 Jun 2011 Planned end date changed from 1 Feb 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com